Robert W. Baird analyst Amanda Sweitzer maintained a Buy rating on Sabra Healthcare REIT (NASDAQ:SBRA) on Wednesday, setting a price target of $18, which is approximately 18.34% above the present share price of $15.21.
Sweitzer expects Sabra Healthcare REIT to post earnings per share (EPS) of -$0.61 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Sabra Healthcare REIT, with an average price target of $18.75.
The analysts price targets range from a high of $20 to a low of $18.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $152.93 million and a net profit of $65.84 million. The company's market cap is $3.36 billion.
According to TipRanks.com, Robert W. Baird analyst Amanda Sweitzer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.6% and a 82.69% success rate.
Sabra Health Care REIT (NYSE:WELL), Inc. engages in managing and investing in healthcare-related real estate properties. It focuses on the acquisition, financing, and owning real estate property to be leased to third party tenants in the healthcare sector. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.